Chinese Researchers Achieve Breakthrough in Neurodegenerative Disease Treatment

Select Language:

Chinese scientists have identified a critical mechanism behind neurodegenerative diseases through years of research and have developed a promising new drug candidate, opening doors to innovative treatments for neurological disorders like multiple sclerosis.

Led by Dr. Shi Fudong, a chief physician at Tianjin Medical University General Hospital’s Department of Neurology, the team discovered that a receptor called formyl peptide receptor 1 (FPR1) plays a central role in initiating inflammation and degeneration within the central nervous system. The findings were published recently in a leading scientific journal.

Building on this discovery, the researchers created a small molecule antagonist targeting FPR1, named T0080, which is now being prepared for human clinical trials.

FPRs are commonly found on white blood cells in mammals and are involved in recognizing and regulating immune responses. In mouse models of multiple sclerosis, the team observed that FPR1 continuously stimulated immune cells to release inflammatory substances, worsening damage to the brain and spinal cord.

Targeting FPR1 presents a new approach for treating multiple sclerosis—a chronic neurological condition affecting young adults—causing issues such as motor dysfunction, vision problems, and, in severe cases, cognitive decline and mental health challenges. Existing treatments mainly aim to relieve symptoms but often struggle to halt ongoing brain injury.

Using computer-assisted drug design, the team screened millions of compounds and identified T0080. Animal tests showed that T0080 could notably decrease brain inflammation and slow neurodegeneration.

This new compound not only holds potential for managing multiple sclerosis but might also be effective against other diseases sharing similar pathological mechanisms, including Alzheimer’s disease, Parkinson’s disease, and strokes.